In:
Clinical Transplantation, Wiley, Vol. 27, No. 4 ( 2013-07)
Abstract:
Wound healing is a known complication associated with sirolimus therapy. Previous studies have demonstrated that obesity is a risk factor for wound‐healing complications ( WHC ) in patients receiving sirolimus therapy; however, the incidence has not been defined. Methods This is a single‐center, retrospective cohort study of de novo kidney transplant recipients ( KTR ) transplanted with a body mass index (BMI) of ≥30 kg/m 2 between January 2002 and April 2011 receiving sirolimus vs. sirolimus‐free maintenance immunosuppression. Results A total of 317 KTR , 71 sirolimus‐free patients and 246 sirolimus patients, were eligible for inclusion. There was no difference in the primary outcome of WHC within six months of transplant (sirolimus 32.1% vs. sirolimus‐free 29.6%, p = 0.107). Sirolimus exposure was not found to influence WHC ( OR 2.906, 95% CI 0.922–9.160); however, BMI Class II ( OR 1.830, 95% CI 1.051–3.186) and Class III ( OR 3.154, 95% CI 1.484–6.705) were significant predictors of WHC . There was no difference in WHC between the sirolimus group and sirolimus‐free group among patients in obesity Class I (27.3% vs. 15.1%, p = 0.064), Class II (36.6% vs. 34.8%, p = 0.195), or Class III (48.0% vs. 53.3%, p = 0.243). Conclusion In our experience, sirolimus does not increase WHC in obese KTR and can be safely used as maintenance immunosuppression immediately following transplant.
Type of Medium:
Online Resource
ISSN:
0902-0063
,
1399-0012
DOI:
10.1111/ctr.2013.27.issue-4
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2739458-X
detail.hit.zdb_id:
2004801-4
Permalink